MONTCLAIR, NJ--(Marketwired - December 19, 2013) - FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased to announce that their Abstract has been accepted for oral presentation at the SNMMI winter meeting which will be held in conjunction with the Annual Meeting of the American College of Nuclear Medicine. Data from FluoroPharma's ongoing Phase II clinical trial for CardioPET (18F FCPHA) to assess myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients, will be presented at the meeting scheduled for February 6-9 in Palm Springs, CA.
Market Data 
Markets 
AI
